Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases Lynk Pharmaceuticals announces FDA IND approval for LNK01006, a novel allosteric TYK2 inhibitor, opening doors to new therapies for neuroinflammatory diseases.

Lynk Pharmaceuticals Achieves FDA Approval for Innovative TYK2 Inhibitor LNK01006 Targeting Neurological Diseases #USA #Boston #Lynk_Pharmaceuticals #LNK01006 #TYK2_Inhibitor